Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047832 | 0.81 | TDP1 (0.39) | KDM4EPKMRPS6KA5 | |
| SCHEMBL30744221 | 0.80 | TSHR (0.34) | IDH1PTGS1PTGS2 | |
| SCHEMBL1750195 | 0.77 | PARP1 (0.38) | IDH1LMNAPOLBLOXKDM4E | |
| SCHEMBL28686868 | 0.77 | GRM4 (0.35) | IDH1LMNAPOLBLOXKDM4E | |
| SCHEMBL3599059 | 0.77 | LOX (0.35) | IDH1LMNAPOLBLOX | |
| SCHEMBL3599060 | 0.75 | ENPP2 (0.35) | IDH1LMNAPOLBLOXKDM4E | |
| SCHEMBL27841654 | 0.75 | HDAC8 (0.33) | IDH1LMNAPOLBLOX | |
| SCHEMBL28938658 | 0.75 | ROCK1 (0.45) | AURKALMNAPOLB | |
| SCHEMBL28022256 | 0.75 | ALOX5AP (0.34) | IDH1LMNAPOLBLOXPTGS1 | |
| SCHEMBL7068250 | 0.75 | IDH1 (0.33) | IDH1GLP1RLOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5539088-A | PROVIDE DYEINGS IN BRILLIANT SHADES WITH GOOD FASTNESS PROPERTIES AND HIGH DEGREE OF FIXATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-07-23 | — | — | US | claimed |
| WO-2026041663-A1 | P2X7 RECEPTOR ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2026-02-26 | — | — | WO | disclosed |
| EP-4685141-A1 | ISOINDOLINE DERIVATIVE, BENZOINDOLE DERIVATIVE AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024193641-A1 | ISOINDOLINE DERIVATIVE, BENZOINDOLE DERIVATIVE AND USE THEREOF | 上海超阳药业有限公司 | 2024-09-26 | — | — | WO | disclosed |
| US-20240124406-A1 | INHIBITORS OF TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117715906-A | Glucagon-like peptide-1 receptor modulators and uses thereof | 和博医药有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-116761795-A | Inhibitors of Transcription Enhancement Associated Domain (TEAD) and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| EP-4164752-A1 | INHIBITORS OF TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11512095-B2 | BCL6 inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-29 | — | — | US | disclosed |
| EP-2951169-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-28 | — | — | EP | disclosed |
| CN-1047778-C | Pyrimido [5-4-d] pyrimidines, drugs containing these compounds, their use and process for preparing them | THOMAE GMBH DR K (DE) | 1999-12-29 | — | — | CN | disclosed |
| US-5770709-A | BRILLIANT COLOR SHADES, GOOD FASTNESS DURING USE AT HIGH DEGREE OF FIXING | DYSTAR TEXTILFARBEN GMBH & CO DEUTSCHLAND KG (DE) | 1998-06-23 | — | — | US | disclosed |
| US-5539088-A | PROVIDE DYEINGS IN BRILLIANT SHADES WITH GOOD FASTNESS PROPERTIES AND HIGH DEGREE OF FIXATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-07-23 | — | — | US | disclosed |
| EP-0675172-A2 | Water-solable azo compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-10-04 | — | — | EP | disclosed |
| US-5197992-A | Disazo dye, naphthol dye with triazole groups for wool, silk, polyamides and cellulose with triphenodioxazines | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-03-30 | — | — | US | disclosed |
| US-5196033-A | BIS-azotriazinyl reactive dyes having an N-alkyl-phenylenediamine link for cellulose textiles | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-03-23 | — | — | US | disclosed |
| US-5059681-A | BIS-AZOTRIAZINYL REACTIVE DYES HAVING AN N-ALKYL-PHENYLENEDIAMINE LINK | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-22 | — | — | US | disclosed |
| CN-1005738-B | Printing method for cellulose fabric | 西巴·盖尔基股份公司 | 1989-11-08 | — | — | CN | disclosed |
| EP-0256650-A2 | Reactive dyes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-02-24 | — | — | EP | disclosed |
| CN-85107872-A | The printing method of cellulose fibre (fabric) | — | 1986-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124406-A1 | INHIBITORS OF TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) AND USES THEREOF | TEAD1, TEAD2, TEAD4 | IDH1 876/4885GLP1R 4434/4885AURKA 3457/4885 |
| US-11512095-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | IDH1 602/4885GLP1R 1872/4885AURKA 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.